Aisthesis Medical raises £900k in pre-seed funding led by TwinPath Ventures to advance its sepsis prediction platform.
TwinPath Ventures led the pre-seed round to help accelerate regulatory clearance and clinical validation for the company's sepsis prediction software.
Aisthesis Medical develops hospital-grade artificial intelligence software designed to predict and prevent life-threatening medical conditions. Its primary platform, VIOSync SPI, helps clinicians anticipate in-hospital sepsis development.
Aisthesis Medical has secured £900k in a pre-seed funding round led by TwinPath Ventures, with participation from TECS Capital. The capital will be directed towards advancing regulatory clearance and expanding clinical validation for its artificial intelligence platform, VIOSync SPI, which aims to predict sepsis in hospital environments up to 48 hours prior to onset.
Sepsis remains a major global healthcare challenge, responsible for millions of deaths annually. The newly acquired funds will support the company as it seeks CE MDR submission, drives hospital pilot deployments, and strengthens its operational team across the UK and the European Union.
From the founder
"I’ve lived through sepsis twice. I know how quickly stability becomes a crisis and how much an earlier insight can change the outcome. With VIOSync we’re giving clinicians a trusted, explainable way to predict risk before symptoms emerge, enabling faster decisions and ultimately saving lives. This funding is a strong validation of our mission and will help us accelerate both regulatory approvals and clinical adoption."
Ioannis Gkouzionis
Co-founder & CEO at Aisthesis Medical
Investor perspective
"Sepsis is a silent killer that has long lacked predictive tools clinicians can trust. Aisthesis Medical’s combination of explainable AI, multimodal data integration, and digital twin technology is uniquely positioned to set a new standard in sepsis care. We are proud to back this exceptional team as they take the next steps towards regulatory approval and market launch."
Katie Lockwood
Partner, TwinPath Ventures
Use of funds
- 01Continue product development
- 02Fund research and development
- 03Expand into international markets
- 04Grow the team
Investors
Categories
About the company
Aisthesis Medical
Aisthesis Medical develops hospital-grade artificial intelligence software to predict and prevent life-threatening clinical conditions.